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Summary
Background Pyronaridine–artesunate is the most recently licensed artemisinin-based combination therapy. WHO has 
recommended that a single low dose of primaquine could be added to artemisinin-based combination therapies to 
reduce Plasmodium falciparum transmission in areas aiming for elimination of malaria or areas facing artemisinin 
resistance. We aimed to determine the efficacy of pyronaridine–artesunate and dihydroartemisinin–piperaquine with 
and without single low-dose primaquine for reducing gametocyte density and transmission to mosquitoes.
Methods We conducted a four-arm, single-blind, phase 2/3, randomised trial at the Ouélessébougou Clinical Research 
Unit of the Malaria Research and Training Centre of the University of Bamako (Bamako, Mali). Participants were 
aged 5–50 years, with asymptomatic P falciparum malaria mono-infection and gametocyte carriage on microscopy, 
haemoglobin density of 9·5 g/dL or higher, bodyweight less than 80 kg, and no use of antimalarial drugs over the past 
week. Participants were randomly assigned (1:1:1:1) to one of four treatment groups: pyronaridine–artesunate, 
pyronaridine–artesunate plus primaquine, dihydroartemisinin–piperaquine, or dihydroartemisinin–piperaquine 
plus primaquine. Treatment allocation was concealed to all study staff other than the trial pharmacist and treating 
physician. Dihydroartemisinin–piperaquine and pyronaridine–artesunate were administered as per manufacturer 
guidelines over 3 days; primaquine was administered as a single dose in oral solution according to bodyweight 
(0·25 mg/kg; in 1 kg bands). The primary endpoint was percentage reduction in mosquito infection rate (percentage 
of mosquitoes surviving to dissection that were infected with P falciparum) at 48 h after treatment compared with 
baseline (before treatment) in all treatment groups. Data were analysed per protocol. This trial is now complete, and 
is registered with ClinicalTrials.gov, NCT04049916.
Findings Between Sept 10 and Nov 19, 2019, 1044 patients were assessed for eligibility and 100 were enrolled and 
randomly assigned to one of the four treatment groups (n=25 per group). Before treatment, 66 (66%) 
of 100 participants were infectious to mosquitoes, with a median of 15·8% (IQR 5·4–31·9) of mosquitoes becoming 
infected. In individuals who were infectious before treatment, the median percentage reduction in mosquito 
infection rate 48 h after treatment was 100·0% (IQR 100·0 to 100·0) for individuals treated with pyronaridine–
artesunate plus primaquine (n=18; p<0·0001) and dihydroartemisinin–piperaquine plus primaquine (n=15; 
p=0·0001), compared with –8·7% (–54·8 to 93·2) with pyronaridine–artesunate (n=17; p=0·88) and 
50·4% (13·8 to 70·9) with dihydroartemisinin–piperaquine (n=16; p=0·13). There were no serious adverse events, 
and there were no significant differences between treatment groups at any point in the frequency of any adverse 
events (Fisher’s exact test p=0·96) or adverse events related to study drugs (p=0·64). The most common adverse 
events were headaches (40 events in 32 [32%] of 100 participants), rhinitis (31 events in 30 [30%]), and respiratory 
infection (20 events in 20 [20%]).
Interpretation These data support the use of single low-dose primaquine as an effective supplement to dihydroartemisinin–
piperaquine and pyronaridine–artesunate for blocking P falciparum transmission. The new pyronaridine–artesunate 
plus single low-dose primaquine combination is of immediate relevance to regions in which the containment of partial 
artemisinin and partner-drug resistance is a growing concern and in regions aiming to eliminate malaria.
Funding The Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Introduction
Gametocytes are the only Plasmodium life stage that can 
be transmitted to mosquitoes. Drugs are a key component 
of malaria control strategies and yet, outside of mass 
drug administration,1 the gametocytocidal component of 
treatment receives little attention. The addition of 
gametocytocidal drugs to first-line malaria treatments 
could benefit control efforts, expedite elimination, and 
slow the spread of parasite strains that are resistant to 
standard schizonticides.2
Pyronaridine–artesunate is a recommended treatment 
for uncomplicated Plasmodium falciparum malaria in 
all malaria endemic regions.3 As the most recently 
licensed artemisinin-based combination therapy (ACT), 
pyronaridine–artesunate is being adopted in areas where 
the efficacy of current first-line and second-line drugs is 
Research in context
Evidence before this study
We searched PubMed on Jan 21, 2021, with no date or language 
restrictions, for studies assessing treatment with pyronaridine–
artesunate (using the search terms “Pyronaridine-artesunate” 
OR “Pyramax” OR “AS-PYR” with down selection based on 
gametocyte detection), or pyronaridine–artesunate plus 
primaquine ([“Pyronaridine-artesunate” OR “Pyramax” OR 
“AS-PYR”] AND “Primaquine”). Among the 16 clinical or 
randomised controlled trials (2010–18) that met the search 
criteria, three studies presented data from a single trial done 
in Kenya (2018), in which gametocytes in patient blood 
were quantified by molecular methods up to 14 days after 
pyronaridine–artesunate treatment (showing 13·9–19·7% 
prevalence at day 14). Further studies were identified in which 
gametocytes present before and after pyronaridine–artesunate 
treatment were quantified by microscopy. None of the 
identified studies determined gametocyte infectivity to 
mosquitoes at any time. Narrowing this search to include 
studies assessing pyronaridine–artesunate in combination with 
primaquine identified only five relevant clinical trials. Two of 
these trials were focused on pharmacokinetic interaction 
between pyronaridine–artesunate and primaquine in healthy 
volunteers. The three other studies determined the safety and 
efficacy of pyronaridine–artesunate plus primaquine for 
treatment of malaria infection: two using a single low dose of 
15 mg, one using the 14-day dosing regimen of primaquine for 
Plasmodium vivax hypnozoiticidal therapy. All three studies 
assessed gametocyte density using microscopy, and none 
determined gametocyte transmissibility.
An additional search of PubMed was done on the same date for 
studies assessing plasmodium infectivity to mosquitoes with 
mosquito feeding assays after any artemisinin-based 
combination therapy (ACT) treatment. For this search we used 
the terms “Malaria” AND (“ACT” OR “Artemisinin” OR 
“Artesunate” OR “Dihydroartemisinin”) AND (“DMFA” OR 
“MFA” OR “Mosquito feeding” OR “Mosquito feeding assay”). 
We identified 12 studies reporting mosquito infection data 
after ACT treatment. Excluding studies without specific 
timepoint identification, three distinct trials measured 
mosquito infection up to day 14 after treatment with 
dihydroartemisinin–piperaquine or artemether–lumefantrine: 
one done in Kenya (with data reported in two publications) 
and two in Cambodia. In one Cambodian study, only three (6%) 
of 48 individuals were infectious to mosquitoes at baseline. 
No studies assessed mosquito infection after day 14 and no 
studies were identified that used mosquito feeding assays 
following pyronaridine–artesunate treatment.
Added value of this study
This is the first clinical trial assessing the malaria transmission-
reducing efficacy of pyronaridine–artesunate treatment alone 
or in combination with single low-dose primaquine, which has 
been recommended by WHO. The results suggest that 
pyronaridine–artesunate treatment alone has little efficacy 
against gametocytes and fails to prevent malaria transmission 
to mosquitoes shortly after treatment, whereas pyronaridine–
artesunate plus single low-dose primaquine is highly effective 
as a schizonticidal and transmission-blocking drug 
combination. In addition to these insights, the study design 
allowed side-by-side comparison of pyronaridine–artesunate 
and pyronaridine–artesunate plus single low-dose primaquine 
with a standard second-line ACT (dihydroartemisinin–
piperaquine), alone and in combination with single low-dose 
primaquine. These data also provide the first direct evidence 
of continued transmission to mosquitoes more than 
14 days after ACT treatment: some individuals treated with 
dihydroartemisinin–piperaquine or pyronaridine–artesunate 
without primaquine continued to infect mosquitoes for up to 
28 days after treatment.
Implications of all the available evidence
The results of this study add to a growing pool of evidence 
supporting the use of single low-dose primaquine alongside 
ACT treatment for the immediate prevention of onward 
Plasmodium falciparum malaria transmission. Before this study, 
the transmission-reducing efficacy of pyronaridine–artesunate 
with or without single low-dose primaquine was unknown. 
Pyronaridine–artesunate is a new and therefore valuable 
alternative antimalarial therapy in areas under threat from 
resistance or partial resistance to current first-line drug 
combinations. The data on the effects of pyronaridine–
artesunate alone provide a resource to policy makers 
considering treatment prioritisation. Our data on the efficacy 
of pyronaridine–artesunate and dihydroartemisinin–
piperaquine with single low-dose primaquine support the 
WHO recommendation that ACTs be combined with single 
low-dose primaquine to rapidly clear gametocytes and prevent 
transmission in areas fighting the spread of antimalarial drug 
resistance or in areas aiming to eliminate malaria.
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decreasing.4 ACT treatment failures are associated with 
higher gametocyte prevalence.5 Regardless of clinical 
treatment outcome, ACTs have low activity against 
mature, transmissible gametocytes.6 Patients treated 
with artemether–lumefantrine or dihydroartemisinin–
piperaquine can still harbour infectious gametocytes 
and these can persist after treatment.7 The duration 
of gametocyte infectivity to mosquitoes following 
ACT treatment is so far poorly defined and has not 
been assessed beyond the first week after treatment. 
Primaquine has potent gametocytocidal activity, with 
studies showing that a single low dose of 0·25 mg/kg is 
sufficient to neutralise infectivity to mosquitoes within 
48 h.8,9 This dose is considered safe in individuals deficient 
in glucose-6-phosphate dehydrogenase (G6PD), who are 
at risk of transient haemolysis after treatment with 
oxidative compounds including primaquine.10 WHO 
currently recommends treatment with ACT and single 
low-dose primaquine without G6PD testing to prevent 
onward P falciparum transmission in areas of artemisinin 
drug resistance or areas aiming for malaria elimination.11 
Given that data from Rwanda have confirmed the de novo 
emergence of kelch13 mutations and associated delayed 
clearance of parasites,12,13 novel ACTs and transmission-
reducing measures, such as single low-dose primaquine, 
could be important components of efforts to avert a public 
health emergency.2
The transmission-reducing efficacy of pyronaridine–
artesunate and pyronaridine–artesunate with single low-
dose primaquine have not yet been tested, and there are 
indications that pyronaridine–artesunate might inhibit 
primaquine metabolism.14 We aimed to assess the efficacy 
of pyronaridine–artesunate with and without single low-
dose primaquine and of dihydroartemisinin–piperaquine 
with and without primaquine for reducing the trans-
mission of P falciparum gametocytes, and to examine 
the long-term duration of gametocyte circulation and 
infectivity to mosquitoes after treatment.
Methods
Study design and participants
We conducted a four-arm, single-blind, phase 2/3, 
randomised controlled trial at the Ouélessébougou 
Clinical Research Unit of the Malaria Research and 
Training Centre of the University of Bamako (Bamako, 
Mali). Screening and recruitment were done in the town 
of Ouélessébougou and surrounding villages. Ethics 
approval was granted by the Ethics Committee of the 
Faculty of Medicine, Pharmacy, and Dentistry of the 
University of Science, Techniques, and Technologies 
of Bamako (Bamako, Mali), and the Research Ethics 
Committee of the London School of Hygiene & Tropical 
Medicine (London, UK). Before the commencement of 
screening, our study team of clinicians and technicians 
met with community leaders, village health workers, and 
heads of households from each village to explain the 
study and obtain approval to conduct the study. Village 
health workers then used a door-to-door approach to 
inform households of the date and location where 
consenting and screening would take place. Participants 
were invited to enrol into the trial if they met the 
following criteria: positive for P falciparum gametocytes 
by microscopy (ie, ≥1 gametocytes recorded in a 
thick film against 500 white blood cells, equating to 
≥16 gametocytes per µL with a standard conversion of 
8000 white blood cells per µL blood); haemoglobin 
density of 9·5 g/dL or higher; age 5–50 years; bodyweight 
less than 80 kg; no clinical signs of malaria, defined 
by fever (≥37·5°C); no signs of chronic or severe 
disease; no allergies to any of the study drugs; and 
no reported use of antimalarial drugs over the past 
week. G6PD status was not tested. Exclusion criteria 
were pregnancy, known allergy to study treatments, 
clinical signs of severe malaria or hepatic injury or renal 
impairment, history of liver disease or renal impairment, 
family history of congenital prolongation of the corrected 
QT (QTc) interval, current or previous treatment with 
drugs metabolised by the enzyme cytochrome P450 2D6 
(CYP2D6) or known to extend the QTc interval, and 
blood transfusion in the past 90 days. Before screening 
and study enrolment, participants provided written 
informed consent (if they were aged ≥18 years), assent 
with written parental consent (12–17 years), or written 
parental consent (<12 years).
Randomisation and masking
Participants were individually randomly assigned (1:1:1:1) 
in blocks of 12, to one of four treatment groups: pyrona-
ridine–artesunate (Pyramax; Shin Poong Pharmaceutical, 
Seoul, South Korea), pyronaridine–artesunate plus single 
low-dose primaquine (primaquine 0·25 mg/kg; ACE 
Pharmaceuticals, Zeewolde, Netherlands), dihydro arte-
misinin–piperaquine (Eurartesim; Sigma Tau, Gaithers-
burg, MD, USA), or dihydroartemisinin–pipera quine with 
single low-dose primaquine. An independent statistician 
at the Malaria Research and Training Centre randomly 
generated the treatment assignment using Stata version 16, 
which was linked to participant identification number. The 
statistician prepared sealed, opaque envelopes with the 
participant identification number on the outside and 
treatment assignment inside, which were sent to the study 
pharmacist. The study pharmacist provided treatment 
according to the contained assignment; consequently they 
and the study physician were not masked to treatment 
assignment, but all other investi gators and staff involved 
in assessing all laboratory outcomes were masked. 
Participants could ask the study physician which treatment 
they received at any time.
Procedures
ACT treatments were administered over 3 days 
(days 0, 1, and 2) under the direct supervision of the trial 
pharmacist, as per manufacturer instructions (appendix 4 
p 2). All treatments were provided with food to facilitate 
See Online for appendix 4
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metabolism. Primaquine tablets (26·3 mg) were dissolved 
to a 1 mg/mL solution in distilled water and administered 
orally according to bodyweight at 0·25 mL/kg (in 1 kg 
weight bands, taking the central point of the band for 
calculation of the 0·25 mg/kg dose) with a fruit-flavoured 
masking fluid, as described previously.8 For example, an 
individual with bodyweight of 50 kg would receive 
12·5 mL of 1 mg/mL primaquine solution for a final dose 
of 0·25 mg/kg. Primaquine was administered as a single 
dose immediately after the first dose of ACT. Individuals 
in the pyronaridine–artesunate and dihydroartemisinin–
piperaquine treatment groups received the same 
volume of masking fluid without primaquine, to equalise 
conditions between groups and to provide participants 
the option of remaining masked to treatment allocation. 
Participants in all treatment groups were treated with a 
full course of dihydroartemisinin–piperaquine at day 21 
of follow-up, to prevent re-infection.
Blood samples were taken for haemoglobin 
density measurement (HemoCue; AB Leo Diagnostics, 
Helsingborg, Sweden), thick film microscopy, and 
molecular analysis of gametocyte density before 
treatment (day 0) and on days 1 (haemoglobin only), 
2, 7, 14, 21, 28, 35, 42, and 49 after treatment (appendix 4 
p 3). Additional blood samples were taken for infectivity 
assessments on days 0, 2, and 7 in all groups. In the 
dihydroartemisinin–piperaquine and pyronaridine–
artesunate groups, blood samples were also taken for 
infectivity assays at days 10, 14, and then at any 
subsequent sampling timepoints if either of the 
previous assays (starting at day 10) had resulted in 
infected mosquitoes.
For infectivity assessments, 75 insectary-reared 
Anopheles gambiae females were allowed to feed for 
15–20 min on venous blood samples (Lithium Heparin 
VACUETTE tube; Greiner Bio-One, Kremsmünster, 
Austria) through a warmed glass membrane feeder 
system (Coelen Glastechniek, Weldaad, Netherlands).15 
Surviving mosquitoes were dissected 7 days after feeding 
and their midguts were stained with a 1% mercurochrome 
solution. The number of oocysts in the lamina of the 
midgut was recorded by trained technicians.
Thick film microscopy was performed as described 
previously,9 with asexual stages counted against 200 white 
blood cells and gametocytes counted against 500 white 
blood cells. For molecular gametocyte quantification, 
EDTA (edetic acid) blood (EDTA VACUETTE tube; 
Greiner Bio-One, Kremsmünster, Austria) was aliquoted 
into RNA protect cell reagent (Qiagen, Hilden, Germany) 
and stored at −80°C until temperature-tracked shipment 
on dry ice to Radboud University Medical Center 
(Nijmegen, Netherlands) for molecular assays. Total 
nucleic acids were extracted using a MagNAPure LC 
automated extractor (Total Nucleic Acid Isolation Kit—
High Performance; Roche Applied Science, Indianapolis, 
IN, USA). Male and female gametocytes were quantified 
in a multiplex reverse-transcriptase quantitative PCR 
(RT-qPCR) assay as described previously (appendix 4 p 4).16 
Samples were classified as negative for a particular 
gametocyte sex if the RT-qPCR-quantified density of 
gametocytes of that sex was less than 0·01 gametocytes 
per μL (ie, one gametocyte per 100 μL of blood sample). 
Clinical and haematological assessments were made on 
all study visits, and adverse events were graded by the 
study clinician for severity (mild, moderate, or severe) 
and relatedness to study medication (unrelated or 
probably not, possibly, probably, or definitely related). 
A drop in haemoglobin concentration by 2 g/dL or more 
between visits to less than 7 g/dL was categorised as a 
haematological adverse event. An external data safety 
and monitoring committee was assembled before the 
trial and discussed safety data after 40 participants were 
enrolled and after the last participant to enrol finished 
their final follow-up visit.
Outcomes
Mosquito infectivity was assessed at three levels: mean 
number of oocysts in a sample of mosquitoes (ie, oocyst 
intensity), the proportion of mosquitoes infected with any 
number of oocysts (ie, mosquito infection rate), and 
infectivity of the study participant to any number of 
mosquitoes (ie, infectious individuals). The primary 
outcome measure was the median percentage change in 
mosquito infection rate at day 2 (48 h after treatment) 
within each group compared with baseline (pre treatment), 
with the same measure at day 7 as a secondary outcome. 
Percentage change was reported as percentage reduction 
(with 100% as total reduction of transmission, and 
negative values as enhanced transmission) and presented 
with IQR. Other secondary transmission outcomes were 
mosquito infectivity (oocyst intensity, mosquito infection 
rate, and infectious individuals) at days 2, 7, and at subse-
quent timepoints in the dihydroartemisinin–piperaquine 
and pyronaridine–artesunate treatment groups (to 
measure duration of infectivity without single low-dose 
primaquine). Secondary gametocyte outcome measures 
for all timepoints were gametocyte density, prevalence, sex 
ratio (ie, proportion of gametocytes that were male), 
circulation time, and area under the curve (AUC) of 
density over time. Safety outcomes at all timepoints were 
haemoglobin density and the total number of adverse 
events (including haematological adverse events). 
Differences in all transmission, gametocyte, and safety 
outcomes were compared between treatment groups as 
secondary comparisons. Some secondary and exploratory 
measures were not included in this report because 
assays could not be completed due to COVID-19-related 
constraints; these were measures of histidine rich 
protein 2/3 (HRP2/3) density, parasite genotyping, and 
molecular measures of asexual parasite density.
Statistical analysis
Sample size was informed by a previous trial at the same 
site and with the same outcomes.9 Earlier data from the 
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same site showed that 79% of individuals infected at least 
one mosquito before treatment, and among those who 
infected at least one mosquito, a median of 24% of 
mosquitoes became infected,8 giving an estimated 
probability of mosquito infection of 0·79 × 0·24=0·190. 
Using a SD of 0·24 for the change in proportion of 
infected mosquitoes before and after treatment (estimated 
from the same data), with 25 participants per group, we 
would have 80% power to detect a 95% or greater reduction 
in infectivity (from 0·190 to 0·009) as significant at the 
0·05 level. With 25 participants per group, we estimated 
we would have 80% power to detect an 80% or greater 
reduction in the proportion of infectious individuals after 
treatment (a secondary outcome) as significant at the 
0·05 level. Therefore, recruitment continued until 
100 participants were enrolled (25 individuals assigned to 
each treatment group). Sample sizes were designed to 
assess reduction in mosquito infectivity over time within 
groups, not between groups (appendix 4 p 5).
Mosquito infection data were analysed at timepoints 
after baseline only for those individuals who were 
infectious at baseline (ie, infecting at least one mosquito 
with any number of oocysts); appendix 4 (pp 6, 8) also 
includes summaries and analyses for all individuals 
regardless of baseline infectivity. The prevalence of 
gametocytes and infectious individuals were compared 
within and between treatment groups using generalised 
linear models (family: binomial, Z score, coefficient with 
95% CI) or Fisher’s exact tests. Absolute haemoglobin 
density and percentage change in haemoglobin density 
(relative to baseline) were compared using paired t tests 
(t score for difference compared with day 0), and 
two-way t tests (t score for difference between ACT matched 
treatment groups [dihydroartemisinin–piperaquine vs 
dihydroartemisinin–piperaquine plus primaquine, pyro-
naridine–artesunate vs pyronaridine–artesunate plus 
primaquine] at each timepoint). The proportion of 
gametocytes that were male was calculated for all values 
Figure 1: Trial profile
100 enrolled and randomly assigned
1044 patients assessed for eligibility
944 excluded
812 gametocyte negative 
106 problems with mosquito husbandry
9 enrolment limit was reached
8 haemoglobin concentration <9·5 g/dL 
3 mixed infections 
2 fever (temperature ≥37·5°C)
2 declined to participate
1 chronic disease (asthma)
1 bodyweight >80 kg
25 received 
pyronaridine–artesunate 
1 withdrew consent after 
day 10
1 withdrew consent after 
day 14
25 included in infection 
analysis 
17 included in primary 
infection subgroup 
analysis (day 2)
8 excluded because of 
no baseline infectivity
25 included in gametocyte 
analysis
25 included in haemoglobin 





1 withdrew consent after 
day 0
1 lost to follow-up after 
day 21
24 included in infection 
analysis 
1 excluded because of no 
follow-up on day 2
18 included in primary 
infection subgroup 
analysis (day 2)
7 excluded because of no 
baseline infectivity
25 included in gametocyte 
analysis
25 included in haemoglobin 




3 withdrew consent after 
day 14
1 withdrew consent after 
day 35
25 included in infection 
analysis
16 included in primary 
infection subgroup 
analysis (day 2)
9 excluded because of no 
baseline infectivity
25 included in gametocyte 
analysis
25 included in haemoglobin 





1 withdrew consent after 
day 2
2 withdrew consent or lost 
to follow-up after day 14
25 included in infection 
analysis 
15 included in primary 
infection subgroup 
analysis (day 2)
1 excluded because of no 
follow-up on day 2
9 excluded because of 
no baseline infectivity
25 included in gametocyte 
analysis
25 included in haemoglobin 
and adverse event 
analyses
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with total gametocyte densities of at least 0·2 gametocytes 
per µL.9 Gametocyte circulation time was calculated to 
determine the mean number of days that a mature 
gametocyte circulates in the blood before clearance, using 
a deterministic compartmental model that assumes a 
constant rate of clearance and has a random effect to 
account for repeated measures on individuals, as described 
previously.17 Difference in circulation time was analysed 
using t tests (t score for difference between ACT matched 
treatment groups). AUC of gametocyte density per 
participant over time was calculated using the linear 
trapezoid method using the first 28 days of observation 
only,18 and was analysed by fitting linear regression models 
to the log10 adjusted AUC values, with adjustment for 
baseline gametocyte density (t score, coefficient with 
95% CI). All other analyses of quantitative data were 
performed using Wilcoxon sign rank tests (Z score for 
difference compared with matched values at day 0) and 
Wilcoxon rank sum tests (Z score for difference between 
ACT matched treatment groups at each timepoint). All 
comparisons were defined before study completion and 
analyses were not adjusted for multiple comparisons. For 
all analyses, the threshold for statistical significance was 
set at p<0·05. Statistical analyses were done using STATA 
version 16.0 and SAS version 9.4.
This trial is registered with ClinicalTrials.gov, 
NCT04049916.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between Sept 10 and Nov 19, 2019, 1044 patients were 
assessed for eligibility and 100 were enrolled and randomly 
assigned to one of the four treatment groups (n=25 per 
group; figure 1). 99 (99%) of 100 participants completed 
the day 2 study visit where the primary outcome measure 
was recorded, and 89 (89%) completed all visits to day 49. 
The final follow-up visit was completed on Jan 7, 2020. 
Participant characteristics were similar between treatment 
groups, although the proportion of male participants 
was lower in the dihydroartemisinin–piperaquine plus 
primaquine group than in the other treatment groups 
(table 1).
The median number of mosquitoes dissected in an 
individual mosquito feeding experiment was 65 (range 
30–75). Before treatment, 66 (66%) of 100 participants were 
infectious to mosquitoes, with a median of 15·8% 
(IQR 5·4–31·9) of mosquitoes becoming infected (table 1).
At 48 h after treatment (day 2), 16 (64%) of 25 participants 
in the pyronaridine–artesunate group, 19 (76%) of 25 in 
the dihydroartemisinin–piperaquine group, none of 25 in 
the pyronaridine–artesunate plus primaquine group, and 
one (4%) of 24 in the dihydroartemisinin–piperaquine 
plus primaquine group infected any number of mos-
quitoes (figure 2, appendix 4 p 6). In individuals who were 
infectious before treatment, the median percentage 
reduction in mosquito infection rate 48 h after treatment 
was 100·0% (IQR 100·0 to 100·0) for individuals 
treated with pyronaridine–artesunate plus primaquine 
(n=18; p<0·0001) and dihydroartemisinin–piperaquine 
plus prima quine (n=15; p=0·0001), compared with 
–8·7% (–54·8 to 93·2) with pyronaridine–artesunate 
(n=17; p=0·88) and 50·4% (13·8 to 70·9) with 
dihydroartemisinin–piperaquine (n=16; p=0·13; table 2).
At day 7, 14 (56%) of 25 participants in the pyronaridine–
artesunate group, 17 (68%) of 25 in the dihydroartemisinin–
piperaquine group, none of 24 in the pyronaridine–artesunate 
plus primaquine group, and one (4%) of 24 in the 















Age, years 12 (9–16) 10 (8–16) 11 (9–14) 10 (7–12)
Sex
Female 12 (48%) 18 (72%) 9 (36%) 13 (52%)
Male 13 (52%) 7 (28%) 16 (64%) 12 (48%)
Haemoglobin, g/dL 12·1 (11·1–12·9) 12·0 (11·0–12·4) 11·9 (11·4–12·8) 11·9 (11·0–13·2)
Gametocyte density by microscopy, parasites per µL 48 (32–80) 80 (48–192) 64 (32–96) 80 (32–144)
Gametocyte density by RT-qPCR,* parasites per µL 74·5 (37·6–126·4) 66·2 (22·9–189·9) 72·8 (26·1–121·7) 59·0 (25·8–146·1)
Asexual parasite prevalence by microscopy 22 (88%) 21 (85%) 13 (52%) 19 (76%)
Asexual parasite density by microscopy, parasites per µL 300 (120–2840) 400 (120–1400) 496 (200–1080) 1640 (400–8800)
Infectious to mosquitoes 16 (64%) 15 (60%) 17 (68%) 18 (72%)
Percentage of mosquitoes infected 23·6% (8·0–37·8) 22·9% (7·8–51·0) 6·2% (3·0–24·0) 9·9% (6·1–29·2)
Data are n (%) or median (IQR). RT-qPCR=reverse transcriptase quantitative PCR. *qRT-PCR data are from individuals from whom baseline RNA samples were available: 25 in 
the dihydroartemisinin–piperaquine group, 24 in the dihydroartemisinin–piperaquine plus primaquine group, 23 in the pyronaridine–artesunate group, and 24 in the 
pyronaridine–artesunate plus primaquine group.
Table 1: Baseline characteristics
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were infectious to mosquitoes (a different infectious 
individual in the dihydroartemisinin–piperaquine plus 
primaquine group on days 2 and 7; figure 2, 
appendix 4 p 6). Mosquito infection rate had increased in 
the dihydroartemisinin–piperaquine and pyronaridine–
artesunate treatment groups by day 7 such that there was 
only a significant within-person reduction from baseline 
in mosquito infection rate in the pyronaridine–artesunate 
plus primaquine and dihydroartemisinin–piperaquine 
plus primaquine treat ment groups (table 2). 13 (54%) of 24 
participants in the dihydroartemisinin–piperaquine group 
and nine (38%) of 24 in the pyronaridine–artesunate 
group infected mosquitoes at day 10 after treatment, 
declining to one (4%) of 23 and one (5%) of 22 by day 28, 
respectively (appendix 4 p 8). Among those individuals 
tested, none infected mosquitoes at day 35 (of n=5 
in the dihydro artemisinin–piperaquine group, n=2 in 
the pyronaridine–artesunate group) or 42 (of n=1 in 
the dihydro artemisinin–piperaquine group, n=1 in the 
pyronaridine–artesunate group; appendix 4 p 8). 
Comparing outcomes between ACT matched treatment 
groups (dihydroartemisinin–piperaquine vs dihydro-
artemisinin–piperaquine plus primaquine, pyronaridine–
artesunate vs pyronaridine–artesunate plus primaquine), 
the addition of primaquine to either treatment resulted 
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Figure 2: Participant infectivity to mosquitoes and percentage of mosquitoes infected in direct membrane feeding assays
Error bars show 95% CI. Significant p values (<0·05) from generalised linear models (family: binary) testing differences within treatment groups with baseline as 
reference are shown. The denominator for participants infectious is the total number of participants still enrolled at the given timepoint, rather than the number 
tested for infectivity at that timepoint. Infectivity assays were discontinued when a participant did not infect any mosquitoes at two subsequent timepoints and were 
thereafter considered non-infectious. Full mosquito infection data including participants infectious with denominator as total participants tested are presented in 
appendix 4 (pp 6, 8). Each line in the plots showing percentage of mosquitoes infected represents an individual. Significant p values (<0·05) from Wilcoxon sign rank 
tests for differences in the median percentage of mosquitoes infected within treatment groups with baseline as reference are shown in appendix 4 (pp 6, 8). 
Timepoints not indicated on the x-axis were not tested. nc=not calculable.
Day 2 Day 7
n Median reduction (IQR) p value* p value† n Median reduction (IQR) p value* p value†
Dihydroartemisinin–piperaquine 
group
16 50·4% (13·8 to 70·9) 0·013 ref 16 34·2% (–11·8 to 88·1) 0·14 ref
Dihydroartemisinin–piperaquine 
plus primaquine group
15 100·0% (100·0 to 100·0) 0·0001 <0·0001 15 100·0% (100·0 to 100·0) <0·0001 <0·0001
Pyronaridine–artesunate group 17 –8·7% (–54·8 to 93·2) 0·88 ref 17 38·9% (–10·6 to 100·0) 0·13 ref
Pyronaridine–artesunate plus 
primaquine group
18 100·0% (100·0 to 100·0) <0·0001 <0·0001 17 100·0% (100·0 to 100·0) <0·0001 0·0001
Median reduction is the median percentage reduction (relative to baseline) in mosquito infection rate at the given timepoints; positive values denote reductions in 
percentage of mosquitoes infected, negative values denote increases. All values are for individuals who were infectious to mosquitoes before treatment (ie, infected any 
number of mosquitoes). Full details of mosquito feeding assay outcomes are shown in appendix 4 (pp 6, 8). *Within-group comparison by Wilcoxon signed rank test 
(day 0 as reference). †Between artemisinin-based combination therapy matched group comparison (ie, dihydroartemisinin–piperaquine vs dihydroartemisinin–piperaquine 
plus primaquine, pyronaridine–artesunate vs pyronaridine–artesunate plus primaquine) by Wilcoxon rank-sum test.
Table 2: Median percentage reduction in mosquito infection rate for individuals who were infectious to mosquitoes before treatment
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grouped average mosquito infection rate, and oocyst 
density by day 2 after treatment (appendix 4 p 6).
Gametocyte densities declined over time in all treatment 
groups, though much more rapidly in those who received 
primaquine, as reflected by the lower circulation time 
and AUC of male and female gametocytes (figure 3, 
appendix 4 pp 9–11). Within each group, gametocyte 
circulation time was similar for male and female 
gametocytes but AUC was lower for male gametocytes, 
reflecting the observed female bias in gametocyte density. 
Decreases in gametocyte density were preceded by a 
decrease in gametocyte infectivity at day 2 after primaquine 
treatment. Gametocyte sex ratios initially showed more 
female gametocytes in all groups (median proportion of 
male gametocytes 0·33 [IQR 0·21–0·49]), but showed 
significantly more male than female gametocytes in the 
dihydroartemisinin–piperaquine plus primaquine group 
by day 7 after treatment (appendix 4 pp 10, 12).
Mean haemoglobin density across all treatment groups 
24 h after the start of treatment was 11·4 g/dL (range 
8·7–15·2), representing a small but significant reduc-
tion in haemoglobin density relative to baseline in the 
dihydroartemisinin–piperaquine (mean change –3·88% 
[95% CI –6·96 to –0·81]), dihydroartemisinin–piperaquine 
plus primaquine (–6·04% [–8·52 to –3·56]), and 
pyronaridine–artesunate plus primaquine (–6·85% 
[–9·81 to –3·88]) treatment groups (appendix 4 pp 13–15). 
Haemoglobin density recovered to baseline levels by 
day 14 in the dihydroartemisinin–piperaquine and 
pyronaridine–artesunate plus primaquine groups, and 
by day 21 in the dihydroartemisinin–piperaquine plus 
primaquine group. At 24 h after treatment, there was a 
significant reduction in average haemoglobin density and 
percentage change in the pyronaridine–artesunate plus 
primaquine group compared with the pyronaridine–
artesunate group (average density difference 0·76 g/dL 
[95% CI 0·02–1·50], average percentage change difference 
4·44% [95% CI 0·30–8·59]); differences between ACT-
matched treatment groups were not significant at any 
other timepoint.
Overall, 75 (75%) of 100 participants experienced a total 
of 173 adverse events during follow-up, 162 (94%) of 
which were categorised as mild severity and 11 (6%) as 
moderate (table 3). There was no difference between 
treatment groups in the proportion of participants who 
experienced an adverse event of mild (p=0·75) or 
moderate (p=0·90) severity (appendix 4 p 16). There were 
no serious adverse events, and there were no significant 
differences between treatment groups at any point in the 
frequency of any adverse events (p=0·96) or adverse 
events related to study drugs (p=0·64). The most 
common adverse events were headaches (40 events in 
32 [32%] of 100 participants), rhinitis (31 events 
in 30 [30%]), and respiratory infection (20 events in 
20 [20%]). No haematological adverse events occurred.
Discussion
This study showed that a single low dose of primaquine 
(0·25 mg/kg) added to either dihydroartemisinin–
piperaquine or pyronaridine–artesunate resulted in total 
or near-total reduction in P falciparum transmission to 
mosquitoes by 48 h after treatment in asymptomatic 
gametocyte carriers in Mali. By contrast, P falciparum 
transmission to mosquitoes continued for up to 28 days 
after treatment with dihydroartemisinin–piperaquine 
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Figure 3: Gametocyte density and prevalence by gametocyte sex
Error bars show 95% CI. On the gametocyte density plots, dots show outliers (1·5 times more than or less than the IQR). Boxplots show gametocyte densities for 
gametocyte-positive individuals only (ie, male or female density >0·01 gametocytes per µL). Tests for differences in gametocyte density (top row) were performed 
using Wilcoxon rank-sum tests and tests for differences in gametocyte prevalence (bottom row) were performed using Fisher’s exact test. p values for female and 
male gametocytes are shown in appendix 4 (pp 9–11). Timepoints not indicated on the x-axis were not tested. Gametocyte circulation time, area under the curve, 
and other secondary outcomes are presented in appendix 4 (pp 9–11).
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findings, gametocyte circulation time and AUC were 
significantly lower in the groups who received primaquine 
than in the non-primaquine groups; however, decreases 
in gametocyte density and changes in gametocyte sex 
ratio were preceded by the observed reduction in 
infectivity.
Pyronaridine–artesunate is being deployed as the first-
line antimalarial in areas of west Africa and has the 
potential to replace current first-line ACTs facing the 
threat of antimalarial drug resistance.19,20 A trial published 
in 2018 showed that pyronaridine–artesunate was non-
inferior to the most widely used ACTs, artemether–
lumefantrine and artesunate–amodiaquine, for the 
treatment of uncomplicated malaria in Mali,19 and 
trials are planned to ascertain the safety and efficacy of 
single-dose and standard pyronaridine–artesunate dose 
regimens for clearance of asymptomatic P falciparum 
infection (NCT03814616). ACTs differ in their efficacy 
against gametocytes, with considerably longer gameto-
cyte persistence following dihydroartemisinin–pipera-
quine than after artemether–lumefantrine.21 Our data 
from highly sensitive sex-specific RT-qPCR assays 
show near identical gametocyte circulation times for 
individuals treated with dihydroartemisinin–piperaquine 
or pyronaridine–artesunate, tentatively supporting 
earlier indications that pyronaridine–artesunate might 
be inferior to artemether–lumefantrine for gametocyte 








































Cough 11 (0) ·· 3 (0) ·· 4 (0) ·· 3 (0) ·· 1 (0) ··
Diarrhoea 2 (0) ·· 0 (0) ·· 2 (0) ·· 0 (0) ·· 0 (0) ··
Fatigue 3 (2) 1 (0) 0 (0) ·· 1 (1) ·· 2 (1) 1 (0) 0 (0) ··
Gastroenteritis 1 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ·· 0 (0) ··
Headaches 1 (0) ·· 0 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ··
Myalgia 1 (0) ·· 0 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ··
Nausea 16 (0) 11 (0) 6 (0) 4 (0) 2 (0) 1 (0) 4 (0) 3 (0) 4 (0) 3 (0)
Pruritus 4 (0) 2 (0) 2 (0) 1 (0) 0 (0) ·· 1 (0) 1 (0) 1 (0) ··
Pyoderma 1 (0) ·· 0 (0) ·· 0 (0) ·· 0 (0) ·· 1 (0) ··
Respiratory Infection 20 (1) ·· 5 (1) ·· 4 (0) ·· 6 (0) ·· 5 (0) ··
Rhinitis 31 (0) ·· 11 (0) ·· 5 (0) ·· 8 (0) ·· 7 (0) ··
Vomiting 9 (0) 6 (0) 2 (0) 2 (0) 1 (0) 1 (0) 32 (0) ·· 3 (0) 1 (0)
Wound 3 (0) ·· 0 (0) ·· 1 (0) ·· 2 (0) ·· 0 (0) ··
Abdominal pain 12 (1) 5 (0) 21 (0) ·· 3 (0) ·· 3 (0) 2 (0) 4 (1) ··
Back pain 1 (0) ·· 0 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ··
Conjunctivitis 1 (0) ·· 1 (0) ·· 0 (0) ·· 0 (0) ·· 0 (0) ··
Dermatophytosis 1 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ·· 0 (0) ··
Dizziness 4 (1) 1 (0) 1 (0) ·· 1 (1) ·· 0 (0) ·· 2 (0) 1
Fever 1 (0) ·· 0 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ··
Headache 40 (6) 9 (1) 8 (1) 8 (3) 6 (2) 2 (0) 16 (2) 2 (0) 10 (1) 2 (0)
Loss of appetite 5 (0) ·· 1 (0) ·· 0 (0) ·· 2 (0) ·· 2 (0) ··
Mumps 1 (0) ·· 1 (0) ·· 0 (0) ·· 0 (0) ·· 0 (0) ··
Scratch on right cheek 1 (0) ·· 0 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ··
Tooth decay 1 (0) ·· 1 (0) ·· 0 (0) ·· 0 (0) ·· 0 (0) ··
Tooth pain 1 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ·· 0 (0) ··
Traumatic red eye 1 (0) ·· 0 (0) ·· 0 (0) ·· 1 (0) ·· 0 (0) ··
Any adverse event 173 (11) 36* (1) 44 (2) 12 (1) 33 (4) 4 (0) 56 (3) 11 (0) 40 (2) 9 (0)
Mild adverse events 162 35 44 11 33 4 56 11 40 9
Moderate adverse 
events
11 1† 2 1 4 0 3 0 2 0
Data are number of moderate and mild adverse events (number of moderate adverse events). There were no serious adverse events. Empty cells indicate absence of adverse 
events linked to drug treatment. Adverse events linked to drug treatment were defined as possibly, probably, or definitely related to treatment. *All 36 adverse events 
classified as linked to the study drug were categorised as expected. †Headache.
Table 3: Adverse events
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gametocyte infectivity,24 and the effect of pyronaridine–
artesunate on transmission to mosquitoes has not 
previously been studied. We assessed the infectivity of 
single infections up to 42 days after treatment, preventing 
re-infection by retreatment with dihydro artemisinin–
piperaquine at day 21.
In efforts to prolong the lifespan of first-line 
antimalarials and stem the spread of emergent resistance, 
supplementing ACTs with low doses of primaquine (as 
recommended by WHO)11 or similar gametocytocidal 
treatments25,26 is likely to become more common. In the 
current study, all treatments were well tolerated clinically, 
with no significant differences in haematological status 
between primaquine and non-primaquine groups after 
the first 24 h from treatment. Indications for antagonism 
of primaquine metabolism by pyronaridine, as might 
have been observed for Plasmodium vivax radical cure,14 
were not observed for P falciparum gametocyte clearance 
or transmission blockade; pyronaridine–artesunate plus 
primaquine treatment resulted in total transmission 
reduction within 48 h, and dihydroartemisinin–pipera-
quine plus primaquine resulted in near-total reduction. 
As in previous studies,8,9 our data show that decreased 
infect ivity after primaquine treatment preceded 
significant changes in gametocyte density or sex ratio, 
supporting the hypothesis that early sterilisation by 
primaquine is due to effects on gametocyte viability 
rather than clearance of one or both sexes of 
gametocyctes.27 Moreover, this study provides a robust 
platform for the evaluation of other potential 
gametocytocidal compounds, such as tafenoquine, which 
might offer an extended period of gametocytocidal and 
sporontocidal activity.25
This study has several limitations. First, we recruited 
high-density gametocyte carriers, which allowed us to 
collect high-quality data on post-treatment transmi-
ssibility,8,9 but does not represent the average gametocyte-
infected individual. Our estimates of (long-term) 
persis tence of transmissible gametocytes therefore reflect 
the effect of antimalarial drugs on transmission potential 
from a relative minority of highly infectious individuals. 
Second, treatment with dihydroartemisinin–piperaquine 
at day 21 in all study groups, to prevent re-infection, meant 
that gametocyte kinetics from day 28 onwards might be 
influenced by this second treatment, although the effect 
of dihydroartemisinin–piperaquine on mature gameto-
cytes is evidently low. Third, our treatment strategy 
circumvented substantial barriers to the more widespread 
adoption of single low-dose primaquine in Africa: drug 
availability and ease of use. At present, primaquine tablets 
are available from a small number of suppliers, at a single 
concentration of 26·3 mg primaquine phosphate 
(equivalent to 15 mg primaquine base). Our approach, in 
which we dissolved the tablets in water, allows precise 
adherence to WHO recommendations with regard to 
dose,11 but it is conceivable that suboptimal primaquine 
doses would be used with more conventional dose 
targeting.28 Optimal dosing strategies will need to consider 
evidence that mg/kg dosing of primaquine results in 
reduced systemic exposure to primaquine in children,29 
and that variations in primaquine metabolism due to 
mutations in the CYP2D6 enzyme might affect primaquine 
efficacy independently of age and weight.30 Finally, 
although we saw significant differences in transmission 
outcomes associated with different treat ments in this trial, 
the public health relevance of these findings must be 
confirmed in community treatment trials with 
transmission endpoints. The effect of gameto cytocidal 
drugs on community-wide transmission will differ with 
recommendations for use and must be considered in such 
trials. Combination with ACTs as part of standard 
treatment might result in only modest effects on wider 
transmission,31 whereas mass drug administration or a 
screen-and-treat approach, which remove more individuals 
from the infectious reservoir, would be likely to have 
greater effect. Practical and financial considerations will 
govern the deployment of such approaches.
Given the concerns about the spread of partial 
artemisinin and partner-drug resistance in southeast Asia, 
alternative effective antimalarial therapies are needed to 
ease drug pressure and maintain treatment efficacy. The 
emergence of de novo kelch13-mutation-associated 
artemisinin resistance in Africa also highlights the 
importance of expanding the arsenal of available 
antimalarial treatments.11,13 Our findings provide further 
evidence that single low-dose primaquine is a safe and 
effective addition to ACTs, including pyronaridine–
artesunate, for blocking P falciparum transmission.
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